Cannabis Report
Home > Boards > US OTC > Miscellaneous >

Vitality Biopharma Inc. (VBIO)

VBIO RSS Feed
Add VBIO Price Alert      Hide Sticky   Hide Intro
Moderator: beachlifeguy
Search This Board: 
Last Post: 6/22/2018 1:48:00 PM - Followers: 58 - Board type: Free - Posts Today: 7

 

 

Vitality Biopharma (“Vitality”) (OTCQB: VBIO) is a cure development company, dedicated to unlocking the power of cannabinoid “prodrugs” as a means to treat serious neurological and inflammatory disorders. We are interested in drug approvals first and foremost, but our overarching mission is to improve the lives of patients afflicted with devastating neurological and inflammatory conditions, such as multiple sclerosis.  We aim to go beyond providing symptomatic relief to patients afflicted with these disorders, such as treatment of muscle spasticity in multiple sclerosis, and to instead identify combination treatments that treat the underlying cause of disease and hold the potential to help patients recover lost function.

Prodrugs are medications or compounds that, after administration, are converted within the body into a pharmacologically active drug, which may already have a long history of clinical investigation and use. Because the reference drug already has independent verification of its safety and efficacy, the prodrug may be approved rapidly through demonstrating similar bioavailability or bioequivalence, and at the same time a prodrug can be far more marketable due to its ability to eliminate unwanted side effects or undesirable commercial aspects. A classic prodrug example is Aspirin, acetylsalicylic acid, which was first made by Felix Hoffmann at Bayer in 1897 and is a synthetic prodrug of salicylic acid.  As of 2015, there were approximately 15 prodrugs that had been classified as blockbusters, defined as having annual sales in excess of $1 billion.

One of the most hotly pursued cannabinoids for pharmaceutical purposes is cannabidiol, which is non-psychotropic, and has demonstrated therapeutic effects in clinical trials for serious neurological conditions including rare seizure disorders and for alleviating symptoms of multiple sclerosis. Our prodrugs could exert the same beneficial therapeutic effects, but with notable improvements, such as a better tasting formulation that enables improved patient compliance, better oral bioavailability that provides safer and more reliable dosing, or a delayed release mechanism that enables patients using these medications to have long-lasting, overnight relief. Given that we have recently filed intellectual property applications including strong composition of matter claims for more than 30 cannabinoid prodrugs, including versions of THC, CBD, and CBDV, we have demonstrated the ability to create a proprietary prodrug of every significant cannabinoid pharmaceutical available today.




Cannabosides – A New Class of Cannabinoid Pharmaceuticals

Vitality Biopharma has developed a new class of cannabinoid prodrugs, known as cannabosides, which upon ingestion can enable the selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract. Site-specific delivery could enable oral drug formulations of cannabinoids to provide therapeutic benefits while reducing or avoiding the systemic delivery of THC into the bloodstream. Currently, high concentrations of psychoactive THC in the brain limit the dose of cannabinoids that can be used elsewhere in the body for treatment of pain and inflammation.

Independent clinical trial results suggest that cannabinoids will help induce remission in Crohn’s disease patients, and that the vast majority of inflammatory bowel disease patients experience symptomatic relief, including more than 75% of patients who report improvement in visceral pain and abdominal cramping. Approximately 1.4 million Americans are affected by inflammatory bowel diseases, including Crohn’s disease and ulcerative colitis. Most patients are diagnosed before age 30 and require life-long treatment.

In addition to providing targeted delivery, cannabosides could enable a better tasting formulation for improved patient compliance, better oral bioavailability that provides safer and more reliable dosing, and a delayed release mechanism that enables patients using these medications to have long-lasting, overnight relief.A prodrug is a medication or compound that, after administration, is metabolized (i.e., converted within the body) into a pharmacologically active drug. Prodrugs are often designed to improve bioavailability when a drug itself is poorly absorbed from the gastrointestinal tract, or to overcome other issues that make molecules unappealing candidates for future development efforts. A prodrug may for instance be used to selectively target a specific tissue or organ, such as the brain or gut, which enables the drug to have a more targeted effect. Prodrugs have been around for a while, with Aspirin, acetylsalicylic acid, first made by Felix Hoffmann at Bayer in 1897, a classic example of a synthetic prodrug of salicylic acid. As of 2015, there were approximately 15 prodrugs that had been classified as blockbusters, defined as having annual sales in excess of $1 billion.


 

Cannabosides – A Novel Class of Cannabinoid Prodrugs
Novel cannabinoid glycoside compositions of matter have reliably lead to dramatic improvements in drug solubility and stability, as evidenced below.
Patents are pending for more than 20 novel cannabinoid glycoside prodrugs (including prodrug versions of of CBD, THC, CBDV, and more).
As federal restrictions on medical research in this field are beginning to relax, and as interest from the public continues to mount, there is a striking increase in the number of clinical trials being sponsored by academic investigators for use of cannabinoids to treat lucrative, large market disease indications.  Given our ability to rapidly create proprietary prodrug versions of each these cannabinoids, we stand to benefit from emerging data, and increasing recognition from the medical community of the potent pain relief and anti-inflammatory effects of cannabinoids.

Studies have shown that cannabinoids can be far more potent than opiates for pain relief, and far more potent than aspirin or corticosteroids for providing anti-inflammatory effects.  Specifically, cannabinoid drugs can be nearly 10 times as potent as opiates for pain relief, including morphine.  Studies have also shown they can be 20 times as potent as aspirin, and twice as potent as corticosteroids for treating inflammation.





 

Our compounds take advantage of a targeted-release mechanism where microbial enzymes present in the intestines will enable a very site-specific localized release of compounds including THC, CBD, and many of the other known cannabinoids. Because of this, we could provide targeted relief of inflammatory bowel diseases (IBD) such as Crohn’s disease or ulcerative colitis, simply by enabling larger doses of cannabinoids to be delivered.

click photo to view presentation

 

Through extensive research in the natural sweetener industry, we pioneered industrial-scale processes to modify stevia to make it taste better. This process is known as glycosylation, which involves adding additional glucose molecules to it, and it modifies both the taste and solubility of it. Over the last 10 years or so, it has become appreciated within the pharmaceutical industry that glycosylation could act to generate new natural product libraries with improved drug properties. This process for modifying natural products to make them more useful is often called glycorandomization, or glycodiversification.

Using the same technology, we’ve now been able to produce and characterize more than 20 novel cannabinoid glycosides, or “cannabosides”, which are novel cannabinoid prodrug pharmaceuticals. As an example, one of the most hotly pursued cannabinoids for pharmaceutical purposes is cannabidiol, which is non-psychotropic, and has potential therapeutic effects in a wide variety of serious neurological and inflammatory conditions. Our prodrugs could exert the same beneficial therapeutic effects, but with notable improvements, such as site-specific delivery that avoids or reduces psychoactivity, a better tasting formulation for improved patient compliance, better oral bioavailability that provides safer and more reliable dosing, and a delayed release mechanism that could enable long-lasting, overnight relief.

Vitality has filed intellectual property applications including strong composition of matter claims for prodrugs of THC, CBD, and CBDV, creating proprietary prodrugs of every significant cannabinoid pharmaceutical available today.





Company News & Media
 

Press Releases

 
Sep 13, 2016 Vitality Biopharma Develops Cannabinoid Alternatives to Opiate Prescription Pain Medications Press Release
Sep 12, 2016 Vitality Biopharma to Present at Rodman & Renshaw 18th Annual Global Investment Conference Press Release
Aug 24, 2016 Vitality Biopharma Announces Expansion of Prodrug Pharmaceutical Portfolio Press Release
Aug 17, 2016 Vitality Biopharma Begins Trading Under New Stock Symbol "VBIO" Press Release
Jul 27, 2016 Vitality Biopharma Advances Cannabosides for Treatment of Inflammatory Bowel Disease Press Release
Jul 19, 2016 Vitality Biopharma Name Change and Corporate Actions Receive Shareholder Approval Press Release
Jun 1, 2016 Vitality Biopharma to Present at LD Micro and BIO Conferences Press Release
May 9, 2016 Launch of Vitality Biopharma for Cannabinoid Prodrug Pharmaceutical Development Press Release
Sep 3, 2015 Stevia First Corp. to Present at Rodman & Renshaw 17th Annual Global Investment Conference Press Release
Aug 25, 2015 Stevia First Corp. Launches Campaign to Divorce Sports World From Sugary Beverages Press Release
 

CEO Blog

What We Should Know About Opiates and Prescription Drug Abuse September 8, 2016
Magnifying the Therapeutic Effects of Medical Marijuana through Targeted Delivery August 9, 2016
Our Company Turns Towards Drug Development and Cannabinoid Pharmaceuticals July 19, 2016
 

In the News


 

 





 

Company Info

Vitality Biopharma, Inc.
1901 Avenue of the Stars
2nd Floor
Los Angeles, California
90067

Telephone: (530) 231-7800
Fax: (866) 293-0655
Email: info@vitality.bio

Cannabis Report
VBIO
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#2062   FDA DENIES VBIO's request for orphan drug designation 236T568 06/22/18 01:48:00 PM
#2061   The SEC investigation of Vitality Biopharma Inc (VBIO) 236T568 06/22/18 01:43:00 PM
#2060   smart beachlifeguy 06/22/18 01:02:54 PM
#2059   I also accumulated a lot of those cheap shares!! Plumberhouston 06/22/18 12:51:35 PM
#2058   They are working on it. They want the Plumberhouston 06/22/18 12:48:07 PM
#2057   Agreed but tough to get through that green light beachlifeguy 06/22/18 12:44:09 PM
#2056   Green light from FDA will propel this to Plumberhouston 06/22/18 11:57:28 AM
#2055   3 days of spams this week. AlphaDog1 06/21/18 10:23:48 PM
#2054   wouldnt complain we gone from $1.10 to $1.70 beachlifeguy 06/21/18 05:24:45 PM
#2053   A little volume here would be nice.... deecon 06/21/18 10:23:25 AM
#2052   Vitality Biopharma Receives DEA Renewal for Cannabinoid Pharma rrojarom 06/21/18 08:54:54 AM
#2051   Things looking up! beachlifeguy 06/20/18 10:21:01 AM
#2049   that took longer than I thought.... beachlifeguy 05/22/18 11:15:41 AM
#2047   Vitality Biopharma Launches Canadian Subsidiary Focused on Cannabinoid superchg2 04/08/18 12:16:05 PM
#2046   Buy low, sell high! superchg2 04/01/18 05:23:32 AM
#2045   FDA DENIES VBIO's request for orphan drug designation [/b 236T568 03/28/18 03:06:10 PM
#2044  Restored ha! you left out the title to the press 236T568 03/28/18 03:04:24 PM
#2043   News beachlifeguy 03/28/18 09:47:51 AM
#2042   Come to Papa.... beachlifeguy 03/27/18 10:58:20 AM
#2041   For once, I have to agree with you. superchg2 03/24/18 01:48:40 AM
#2040   SEE...THE MARKET DOES NOT GIVE A RIP, PEOPLE beachlifeguy 03/22/18 09:56:17 AM
#2039   AND ONCE AGAIN THE MARKET DOES NOT GIVE beachlifeguy 03/20/18 03:35:03 PM
#2038   actually, that is NOT going to happen 236T568 03/20/18 02:49:19 PM
#2037   The VBIO application that was DENIED by the FDA 236T568 03/20/18 02:47:27 PM
#2036   oops, you seem to have left out the 236T568 03/20/18 02:44:03 PM
#2035   "The FDA recently announced that it no longer superchg2 03/20/18 02:21:40 PM
#2034   "For now.... " WHAT? 236T568 03/20/18 01:01:02 PM
#2033   8K form beachlifeguy 03/20/18 12:58:02 PM
#2032   For now.... beachlifeguy 03/20/18 12:56:56 PM
#2031   FDA DENIES VBIO's request for orphan drug designation 236T568 03/20/18 11:31:57 AM
#2030   what do you expect them to say? beachlifeguy 03/20/18 11:03:33 AM
#2029   "So, we expect 2018 will be a momentous year" superchg2 03/20/18 10:59:17 AM
#2028   Shareholder letter beachlifeguy 03/19/18 10:50:53 AM
#2027   Cannabis as an effective treatment for autism. superchg2 03/12/18 10:53:06 AM
#2026   Me too. superchg2 03/09/18 12:27:49 AM
#2025   Hoping for a dip to get back in...$1.30- beachlifeguy 03/08/18 12:57:38 PM
#2024   I'm still accumulating at these low prices. Plumberhouston 03/08/18 08:16:05 AM
#2023   Once the FDA signs off on the orphan superchg2 03/07/18 10:05:33 AM
#2022   And still no one gives a rip beachlifeguy 03/05/18 12:35:05 PM
#2021   The SEC investigation of Vitality Biopharma Inc (VBIO) 236T568 03/05/18 12:30:53 PM
#2020   LOVE IT, spreading the word! beachlifeguy 03/05/18 12:27:42 PM
#2019   since when hiring a promotion co. free? beachlifeguy 03/05/18 11:11:01 AM
#2018   2% drop not really a timber moment beachlifeguy 03/05/18 11:09:03 AM
#2017   VBIO - STOCK PROMOTIONS 236T568 03/05/18 10:42:17 AM
#2016   TIMBER! 2.4 million freely trading VBIO shares to 236T568 03/05/18 10:37:26 AM
#2015   The next couple of months will be very superchg2 02/17/18 02:33:55 PM
#2014   They are grinding out the IND. Plumberhouston 02/17/18 11:46:18 AM
#2013   It's just a continuation of the original SEC superchg2 02/16/18 03:13:07 PM
#2012   Notice how these filings never affect SP or beachlifeguy 02/16/18 02:38:01 PM
#2011   Waiting for the IND to be submitted. superchg2 02/15/18 05:00:27 PM
PostSubject